Poorer Outcomes With Rituximab + Chemo in Heavier Patients, Older Men With Follicular Lymphoma

May 29-June 2, 2015; Chicago, Illinois
Retrospective analysis suggests that subsets of patients with FL may receive suboptimal doses of rituximab.
Format: Microsoft PowerPoint (.ppt)
File Size: 464 KB
Released: June 5, 2015

Acknowledgements

Educational grant provided by:
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Bristol-Myers Squibb
Celgene Corporation
Genentech BioOncology
Incyte
Novartis Pharmaceuticals Corporation

Related Content

Commentary from Dr. John Leonard on factors he uses to select mantle cell lymphoma therapy, from Clinical Care Options (CCO)

John P. Leonard, MD Released: July 29, 2021

Clinical commentary featuring expert insights on key CLL studies with BTK inhibitors from ASCO and EHA 2021 from Clinical Care Options (CCO)

Anthony Mato, MD, MSCE William G. Wierda, MD, PhD Released: July 28, 2021

Clinical commentary from European hematology experts on key clinical trials presented at the virtual EHA 2021 meeting, from Clinical Care Options (CCO)

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, FMedSci María-Victoria Mateos, MD, PhD Lydia Scarfò, MD Ali T. Taher, MD, PhD, FRCP Released: July 28, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue